INCY News and Press, Incyte Corporation From 02/12/21

There is no cure for alopecia areata and the latter affects as many as 6.8 million people in the U.S. alone. Concert is among the several companies developing a drug and it aims to present an NDA submission in early 2023. However, I doubt it will be the first to reach the market a...

Incyte Corporation (INCY) has been downgraded to Underperform from Market Perform at SVB Leerink after the release of the company’s Q4 2020 financial results where the top-line rose ~36.3% YoY outperforming the ~12.8% YoY increase in the cost of product sales.The analyst Andrew Be...

Incyte Corporation (INCY) Q4 2020 Earnings Conference Call February 9, 2021 8:00 AM ET Company Participants Mike Booth – Head of Investor Relations Hervé Hoppenot – Chairman, President and Chief Executive Officer Barry Flannelly – Executive Vice President and General...

Incyte (NASDAQ: INCY) hasn't exactly been a highflier in recent years. Over the last five years, the stock is up less than 30%. During that same period, the S&P 500 more than doubled. The biotech reported its fourth-quarter results before the market opened on Tuesday. Di...

Image source: The Motley Fool. Incyte Corp (NASDAQ: INCY) Q4 2020 Earnings Call Feb 9, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Incyte Corp (INCY) Q4 2020 Earnings Call Transcript

Incyte (INCY) Q4 results:Revenues: $789.5M (+36.3%); Jakafi: $516.8M (+11%); Iclusig: $28.6M (+18%); Jakavi product royalty: $87.06M (+34%); Olumiant product royalty: $30.9M (+31%); Pemazyre revenue: $14M; Tabrecta royalty revenue: $2M.Net Income: $149.85M (...

Incyte (INCY): Q4 Non-GAAP EPS of $0.93 beats by $0.16; GAAP EPS of $0.68 beats by $0.16.Revenue of $789.5M (+36.3% Y/Y) beats by $134.61M.Press Release For further details see: Incyte EPS beats by $0.16, beats on revenue

- Total FY revenues of $2.67 billion (+24% y/y); total FY product and royalty revenues increased 18% to $2.46 billion; three new FDA approvals in 2020 - Jakafi ® (ruxolitinib) FY revenue increased to $1.94 billion (+15% y/y); Jakafi ® guidance range of $2.125...

Investors should always be mindful of the market environment, perhaps now more than ever. Despite sweeping political changes in Washington, COVID-19 continues to keep investors guessing as to what lies ahead for the broader U.S. economy. Still, some companies are going to grow regardles...

Incyte ([[INCY]] -1.9%) announces that the European Medicines Agency's ((EMA)) Committee for Medicinal Products for Human Use ((CHMP)) has issued a positive recommendation for its marketing application of pemigatinib for the treatment of certain adults with a form of unresectable locally adva...